MRNA vaccine side effects – Oxford researchers are alarmed by studying cerebral venous thrombosis

a A new study from the University of Oxford It appears harmless at first: therefore, the risk of rare strokes is significantly higher in the case of corona infection than after vaccination against the virus. The risk of developing Covid-19 disease is much higher, especially for sinus venous thrombosis (SVT) focused on with the AstraZeneca vaccine.

This was already known in principle, but Oxford researchers have now given the risk of such a blood clot a more subtle factor: After contracting Coronavirus, it is about 100 times higher than normal. Compared to the available vaccines, the risk is 8 to 10 times higher. This sounds like good news for everyone who wants to be vaccinated: Covid-19 is a much greater risk than vaccination.

But with Covid-19 vaccines available, the study isn’t just about the drug AstraZeneca, which is only used on a limited scale in many countries because of these clots. It also certifies that vaccines from Biontech / Pfizer and Moderna used in Switzerland have practically the same risks. That would be new and maybe even worrisome. But it is not that easy.

The results are currently only available as an introduction to print and have not yet been verified by other scholars. They now fiercely criticize the vaccine comparison and the statement that the risk is roughly the same for the three manufacturers.

Oxford co-developed the AstraZeneca vaccine

First of all, it should be noted that the University of Oxford, which conducted the study, developed the AstraZeneca vaccine in cooperation with the Swedish pharmaceutical company. So in the UK it is known as the Oxford vaccine. The university maintains that the study authors worked independently of the vaccine developers. It can hardly be verified.

Then the study authors themselves indicated that the results of the study of nearly 500,000 Covid patients should be interpreted with caution, as more data will be added with more vaccines. Only cases were examined from the USA, as Moderna and Biontech, but AstraZeneca not. Therefore the comparability is called into question.

The criticism of fellow specialists is, among other things, about the numbers collected. This is how they were calculated: of the 513,000 people diagnosed with coronavirus, 20 were diagnosed with sinus venous thrombosis – this corresponds to an extrapolation of 39 cases per million people. In the case of mRNA vaccines, there were two reports within two weeks of vaccination, in 490,000 people – an extrapolation of approximately 4 cases per million people.

US authorities presented completely different numbers

Are both cases really true? There are always incorrect reports or incorrect entries, with very few instances the wrong crossbreeding can change a lot. Ultimately, 490,000 vaccines were screened through March 25, 2021, but during this time, the United States administered more than 100 million vaccine doses.

There are now more than 200 million, and the latest side-effect report now gives an indication of the accuracy of the Oxford numbers: The U.S. Department of Health’s Advisory Committee on Immunization Practices (ACIP) did this week He presented his new report. Accordingly, there was not a single sinus vein thrombosis after vaccination with 98 million doses of Biontech. Approximately 85 million doses of Moderna have been administered and 3 cases have been reported.

In short, that would be 3 cases per 183 million vaccines or 0.016 cases per million people – 250 times less than what the Oxford study found, which is a very big difference. It is almost impossible to explain how this difference occurred.

There is no thrombosis in a cerebral vein in Switzerland

In Switzerland, Swissmedic did not report any cases of sinus vein thrombosis following vaccination with Biontech or Moderna last week. In Germany, according to the Paul Ehrlich Institute responsible for vaccine safety, there have been at least 7 cases out of 10.7 million vaccines, which is still six times less than what was reported in the Oxford study. The institute also states: “Given the vaccinated doses, the number of reported cases is not higher than the expected number of sinus thrombosis.” Such clots also occur without fertilization, so the observed number corresponds to the average. This was not the case at AstraZeneca, as it was more statistically than expected, the Paul Ehrlich Institute writes.

The occurrence of sinus venous thrombosis (SVT) alone is not conclusive, however, and is another criticism of the Oxford study. It becomes especially dangerous if there is a simultaneous occurrence of thrombocytopenia (thrombocytopenia). In Germany, after the vaccination of AstraZeneca, 23 cases of SVT and concurrent platelet deficiency were found, and five women and three men died. This phenomenon was also observed after the administration of the Johnson & Johnson vaccine, in three out of six cases, which is why it has been discontinued for now.

Platelet deficiency is crucial

Experts agree that platelet deficiency is the critical factor in blood clotting. The Oxford study never investigated this nor provided any figures for it. However, health authorities have the numbers: in the thromboses observed after vaccinations Moderna or Biontech, there was no case with concurrent thrombocytopenia, neither in the United States nor in Germany. This applies not only to sinus veins, but also to all types of proven thrombosis that did not occur statistically more frequently than expected.

According to figures released by safety authorities, there is no increased risk of developing sinus thrombosis in Biontech or Moderna. Critics of the study complain that the Oxford study mixed apples with pears. In fact, the main message of the investigation will be important, that Covid-19 disease carries a much higher risk of SVT than vaccination.

Covid also carries many other dangers

Whereas, coagulation with concomitant deficiency of platelets, as has been observed only in AstraZeneca or Johnson & Johnson at present, is the only risk for people who are not allergic to vaccines. Thrombosis is a common problem with Coronavirus, but there are many other complications and risks that threaten sufferers. Scientists say this is one reason the study has faltered so badly.

Finally, the study does not apply to the world at large, because in countries with a virus-free strategy, the risk of infection has been largely avoided. The risk evaluation will likely be different depending on the age group.